UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.83) by 33.73 percent. This is a 19.12 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $25.20 million which beat the analyst consensus estimate of $24.20 million by 4.13 percent. This is a 20.87 percent increase over sales of $20.85 million the same period last year.